Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (SE:CEVI)
:CEVI
CEVI Stock Chart & Stats
kr161.00
-kr3.60(-2.10%)
At close: 4:00 PM EST
kr161.00
-kr3.60(-2.10%)
Day’s Range― - ―
52-Week Rangekr139.20 - kr208.00
Previous CloseN/A
Volume5.79K
Average Volume (3M)36.08K
Market Cap
kr3.66B
Enterprise Valuekr3.50B
Total Cash (Recent Filing)kr188.22M
Total Debt (Recent Filing)kr25.65M
Price to Earnings (P/E)23.9
Beta0.86
Next Earnings
Apr 24, 2026EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend Yield1.61%
Share Statistics
EPS (TTM)1.80
Shares Outstanding23,851,547
10 Day Avg. Volume30,505
30 Day Avg. Volume36,083
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Margins & ProfitabilityCellaVision's consistently high gross and operating margins indicate durable product-level economics and pricing power in diagnostic imaging. Strong margins support reinvestment in R&D and steady returns to equity holders, insulating profitability through modest revenue volatility.
Very Conservative Balance SheetNear-zero leverage provides significant financial flexibility for product investment, M&A or to weather demand cycles. Low debt reduces refinancing risk and interest burden, preserving cash flow for strategic projects and protecting returns during industry slowdowns.
Product Pipeline & Recurring RevenueRegulatory progress (bone marrow CE submission) and completed software upgrades strengthen the addressable market and attachment/recurring revenue potential. Clinical milestones plus software installs improve long-term adoption, stickiness, and predictable license/service revenues.
Bears Say
Sharp Recent Revenue DeclineA pronounced TTM revenue drop signals structural demand weakness or lost share that can persist across quarters. Even with healthy margins, sustained top-line contraction pressures scale economics, limits reinvestment capacity and raises execution risk for strategic initiatives.
Weak Free-cash-flow ConversionLow FCF conversion and volatility—driven by higher working capital—reduce the company's ability to self-fund R&D, dividends or bolt-on investments. Chronic conversion weakness increases reliance on operational improvement or external financing to support long-term growth plans.
APAC/China CompetitivenessIntense local competition and pricing pressure in China/APAC limit durable margin expansion and market share gains in high-growth regions. Local manufacturing steps help but competitive dynamics may compress long-term growth and require sustained commercial investment.
CellaVision AB News
CEVI FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was kr139.20 and its highest was kr208.00 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr3.66B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Apr 24, 2026 which is in 67 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Feb 05, 2026. The company reported kr1.8 earnings per share for the quarter, beating the consensus estimate of kr1.311 by kr0.489.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB pays a Annually dividend of kr2.5 which represents an annual dividend yield of 1.61%. See more information on CellaVision AB dividends here
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 1.6.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr1.8 in its last earnings report, beating expectations of kr1.311. Following the earnings report the stock price went up 11.348%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in SE:CEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
CEVI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.View all SE:CEVI earnings summariesTechnical Analysis
BICO Group AB Class B
―
Senzime AB
―
Xvivo Perfusion AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---